Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dilazep is a small molecule vasodilator that acts primarily as an adenosine reuptake inhibitor. It exhibits antiplatelet, antianginal, and vasodilator properties. By inhibiting the cellular uptake of adenosine via equilibrative nucleoside transporter 1 (SLC29A1), it increases extracellular adenosine concentrations, leading to vasodilation and inhibition of platelet aggregation. Dilazep also improves blood flow in coronary and renal vessels, protects cardiac muscle, reduces proteinuria in renal dysfunction, and is used clinically for the treatment of ischemic heart disease (including angina), cerebral ischemia, and certain renal disorders[1][3][4][5][7]. Its mechanism includes reducing thromboxane B2 formation by impairing arachidonic acid release from platelet membranes[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dilazep.